Table 3.

Univariate and multivariate analysis of overall survival and disease-free survival.

Factors		Univariate analysis		Multivariate analysis
		HR (95% CI)	p value	HR (95% CI)	p value
OS
Age	<35, 35~60, >60	1.343 (0.745–2.424)	0.327	2.737 (1.350–5.551)	0.005
Pathology	IMPC, IDC	0.905 (0.487–1.683)	0.752	0.727 (0.358–1.478)	0.379
TNM stage	I, II, III	3.590 (1.952–6.603)	<0.001	2.822 (1.362–5.850)	0.005
LVIa	Negative, positive	2.934 (1.133–7.601)	0.027	1.575 (0.528–4.696)	0.415
HRb status	Negative, positive	0.361 (0.176–0.738)	0.005	0.277 (0.106–0.722)	0.009
HER2c status	Negative, positive	1.083 (0.529–2.218)	0.827	0.833 (0.331–2.092)	0.697
DFS
Age	<35, 35~60, >60	0.676 (0.457–1.001)	0.051	0.888 (0.564–1.397)	0.606
Pathology	IMPC, IDC	0.901 (0.601–1.352)	0.616	0.944 (0.601–1.481)	0.802
TNM stage	I, II, III	3.082 (2.155–4.408)	<0.001	2.665 (1.731–4.103)	<0.001
LVI	Negative, positive	2.053 (1.204–3.502)	0.008	0.960 (0.513–1.799)	0.900
HR status	Negative, positive	0.786 (0.429–1.441)	0.437	1.059 (0.517–2.167)	0.876
HER2 status	Negative, positive	1.554 (1.007–2.399)	0.046	1.314 (0.798–2.166)	0.284

LVI^a: lymphovascular invasion.

HR^b: hormone receptor.

HER2^c: epidermal growth factor receptor 2.